Who can expect to get the COVID-19 antiviral pill in B.C., and how many will be available?
There's another tool in the fight against COVID-19 and B.C.'s top doctor said it will help prevent more serious illness if it's given to people early on.
Health Canada authorized the use of Pfizer's COVID-19 antiviral treatment Paxlovid Monday, and it's the first oral and at-home prescription medication to be cleared for use in the country.
In a news conference Tuesday, Dr. Bonnie Henry said the antiviral treatment is designed specifically for individuals at the highest risk of developing more severe illness and ending up in hospital.
"It includes those people in our community who are over age 70, clinically extremely vulnerable, immune compromised and for younger people who have additional medical conditions and don’t have the protection of vaccines."
Henry said B.C. can expect a limited supply of 4,000 treatment doses within the next few weeks.
The prescription-only medication must be started within five days of the onset of symptoms.
Henry added that the province is working with its clinical care advisory team to distribute the treatment where it can be the most effective.
"This is very good news. It's not going to change the trajectory of our pandemic right now but it's another tool to help those people who are more at-risk of ending up in hospital," she said.
University of British Columbia associate professor and drug safety researcher Mahyar Etminan said the treatment should not be viewed as a magic bullet.
"We don’t really have any data on children or healthy adults," he said. "So primarily, it was studied in adults who had COVID symptoms and had one other medical condition."
Etminan said the efficacy numbers being shared by the company for the treatment also need to be put in perspective.
"Unfortunately, the way they presented the data is this relative risk reduction metric, which tends to sort of overestimate the efficacy," he said, and noted Pfizer has reported an 88 per cent reduction of either hospitalization or death relative to the placebo group.
"In absolute numbers, it’s about a six per cent benefit...if 16 such participants took the drugs, one would benefit."
Etminan said roughly a thousand adults were part of the Pfizer study that received the antiviral combination, which helps prevent the replication of COVID in the body. He said a similar number were given a placebo.
"It’s also important to know that the data we have is data provided by the company," he said. "We still don’t have any peer-reviewed data from this study."
Etminan said based on the available data, "it seems like it should really be intended for adults who are at a high-risk of morbidity or dying from COVID."
"It comes down to risk versus benefits," he said. "It seems from the data we have that that sort of demographic would, right now at least, benefit the most from this drug."
Two additional vaccines, Medicago and Novavax, continue to be under review by Health Canada.
"We were hoping (Novavax) would be approved sometime in January, but it looks like it's more likely to be in February and Medicago may be as early as the end of January or February," Henry said.
"So I think that's important for those people who have made that determination that the mRNA vaccines that we have, and are holding out for something else. It's not going to be available to help you through this wave. But it is an additional option that will be coming, we hope, in the near future."
CTVNews.ca Top Stories
Two killed after collision with truck on Hwy. 417 near Limoges, Ont.
Ontario Provincial Police say two people were killed after a car and a transport truck collided in the westbound lanes of Highway 417 near Limoges, Ont. on Tuesday afternoon.
Houston braces for flooding to worsen in wake of storms
High waters flooded neighborhoods around Houston on Saturday following heavy rains that have already resulted in crews rescuing hundreds of people from homes, rooftops and roads engulfed in murky water.
Canadian doctor concerned new weight-loss drug Wegovy may be used inappropriately
As Wegovy becomes available to Canadians starting Monday, a medical expert is cautioning patients wanting to use the drug to lose weight that no medication is a ''magic bullet,' and the new medication is meant particularly for people who meet certain criteria related to obesity and weight.
What a U.S. farmworker’s case of bird flu tells us about tracking the infection
A U.S. farmworker who caught bird flu after working with dairy cattle in Texas appears to be the first known case of mammal-to-human transmission of the virus, a new study shows.
‘We made them safer and more fun’: Here’s what’s new about e-scooters
Electric scooters (e-scooters) have been gaining popularity in the capital and this season comes with some changes and updates.
Hulk Hogan, hurricanes and a blockbuster recording: A week in review of the Trump hush money trial
Crucial witnesses took the stand in the second week of testimony in Donald Trump's hush money trial, including a California lawyer who negotiated deals at the center of the case and a longtime adviser to the former president.
A Chinese driver is praised for helping reduce casualties in a highway collapse that killed 48
A Chinese truck driver was praised in local media Saturday for parking his vehicle across a highway and preventing more cars from tumbling down a slope after a section of the road in the country's mountainous south collapsed and killed at least 48 people.
Grandparents killed in wrong-way crash on Hwy. 401 identified
A 60-year-old man and a 55-year-old woman killed in a wrong-way crash on Highway 401 earlier this week have been identified by the Consulate General of India in Toronto.
Canadian Auger-Aliassime reaches first Masters final in Madrid with another walkover
Montreal's Felix Auger-Aliassime has advanced to his first ATP Masters final, and he hasn't had to play all that much tennis to do it.